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Abstract
The renin–angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular
disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension
and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction.
This review presents the history of RAAS inhibition including a summary of key heart failure,
myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS
inhibition are discussed including implementation and optimization of current drug therapies.
Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and
approvability of novel RAAS inhibitors are highlighted.
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1. Introduction
The renin–angiotensin aldosterone system (RAAS) is central to the pathogenesis of
cardiovascular disease through vascular inflammation, an increase in reactive oxygen
species, endothelial dysfunction, and atherosclerosis with subsequent complications such as
myocardial infarction (MI), chronic heart failure (HF) and renal disease [1]. Medications
inhibiting the RAAS such as angiotensin-converting enzyme inhibitors (ACE-Is),
angiotensin receptor blockers (ARBs) and mineralocorticoid receptor antagonists (MRAs)
are several of the most significant advances in cardiovascular medicine [2,3]. Since the
CONSENSUS trial over 20 years ago [2], the field has seen multiple strategies of RAAS
inhibition with varying success from single drug optimization to combination therapies. We
provide an overview of the history of RAAS inhibition, discuss recent RAAS developments
and present practical ways to overcome the challenges of drug optimization. Finally,
ongoing clinical trials, opportunities for future trials and issues related to the barriers and
approvability of novel RAAS inhibitors are highlighted.
2. RAAS background
RAAS is the hormone system that regulates intravascular volume, blood pressure and tissue
repair via inflammatory and proliferative mechanisms (Fig. 1). While protective during an
acute stress response, chronic stimulation has detrimental effects including vasoconstriction,
vascular smooth muscle proliferation, endothelial dysfunction, inflammation, fibrosis, and
thrombosis [4]. The RAAS cascade begins when renal juxtaglomerular cells secrete renin in
response to renal hypoperfusion, decreased sodium delivery, and sympathetic activation [5].
Plasma renin converts hepatically produced angiotensinogen to inactive angiotensin I. ACE
cleaves angiotensin I to generate angiotensin II (AII). Only approximately 10% of ACE
circulates in the plasma and controls acute hemodynamic modulation, whereas tissue-
specific RAAS uses local angiotensin I to form AII. Independent of ACE activity, serine
proteases are also capable of converting angiotensin I to AII. Although the peripheral or
circulating RAAS may be involved in cardiovascular remodeling and restructuring, it is the
autocrine or paracrine production of AII that may be most important in promoting these
changes [6,7]. AII is responsible for vasoconstrictive, proliferative and pro-inflammatory
effects while the actions of angiotensin-(1–7) mainly oppose those of angiotensin II [8].
ACE hydrolyzes angiotensin-(1–7) into its inactive form, such that ACE-Is result in greater
availability of angiotensin-(1–7) with its vasodilatory and antiproliferative actions. AII
stimulates adrenal cortex secretion of aldosterone and posterior pituitary secretion of
arginine vasopressin with resultant volume expansion. Aldosterone is also regulated through
non-AII pathways and is involved in sodium and potassium homeostasis. Above and beyond
their renal actions, AII and aldosterone exert synergistic and independent systemic and
autocrine/paracrine pleiotropic effects that result in myocardial and vascular remodeling
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[5,9]. AII promotes atherogenesis through effects on smooth muscle cell growth and
migration, macrophage activation and vascular invasion, inhibition of apoptosis, increased
oxidative stress and stimulation of thrombosis [10]. RAAS inhibition has been shown to
positively impact disease progression via these mechanisms [10]. Given the impact of the
RAAS on metabolic signaling, oxidative stress, and endothelial dysfunction, a role for
RAAS inhibitors has been supported to prevent or delay the development of type 2 diabetes
via effects on insulin sensitivity and signal transduction [11]. Pleiotropic effects of
aldosterone include an increase in reactive oxygen species, endothelial dysfunction,
apoptosis, inflammatory cytokine activation, and collagen formation [12,13]. The
association between genetic variants of the RAAS and blood pressure response to RAAS
inhibitors and clinical outcomes has been inconsistent [14]. Recent data suggesting that
polymorphisms of the RAAS may be associated with hypertension and reduced systolic
function require further evaluation and confirmation [15].
3. Contemporary RAAS inhibitors
The three main classes of RAAS inhibitors currently used in clinical practice are ACE-Is,
ARBs and MRAs with a fourth class of agents – the direct renin inhibitors (DRIs) – under
active investigation (Fig. 2). ACE-Is decrease the formation of angiotensin II and inhibit the
breakdown of bradykinin with the formation of nitric oxide and other vasodilators [16]. For
patients intolerant of ACE-Is, ARBs may represent an alternative. ARBs bind competitively
to and dissociate slowly from AT1 receptors [17]. The observed differences in lipid
solubility, plasma protein binding, bioavailability, plasma half-life, and systemic elimination
for these agents influence their onset, duration of action, and efficacy in blocking tissue
RAAS which impacts their cardiovascular protection profiles [18]. The difference between
the dose requirement to reduce blood pressure and that needed to achieve cardiovascular
protection varies based on the pharmacokinetic profiles of RAAS inhibitors even within the
same general therapeutic class [19]. MRAs reduce the number of available epithelial sodium
channels in the distal renal tubule through competitive inhibition of the mineralocorticoid
receptor. Eplerenone is a more selective mineralocorticoid receptor blocker with lower
affinity for progesterone and androgen receptors than spironolactone [20]. Conventional
agents that block RAAS induce a reflex increase in renin which may lead to RAAS ‘escape’.
DRIs inhibit the RAAS at the most proximal, specific, and rate-limiting step [21]. Aliskiren
is the only currently available DRI with approval for use in hypertension.
4. Heart failure
Since the CONSENSUS and SOLVD trials first demonstrated the effectiveness of ACE-Is in
chronic HF with left ventricular systolic dysfunction (LVSD) over 20 years ago (Table 1)
[2,22], multiple trials have demonstrated the beneficial effects of ACE-Is on clinical status,
neurohormonal activation, quality of life, HF hospitalization and survival [23]. ACE-Is
reduce the risk of death due to HF, sudden cardiac death, and MI in a broad range of patients
with LVSD [23]. Conversely, the PEP-CHF trial investigating the use of ACE-Is in patients
with HF and a preserved left ventricular ejection fraction (HFpEF) did not show improved
outcomes [24].
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With regard to ARBs, the CHARM-Alternative study demonstrated that candesartan use in
symptomatic HF patients with LVSD reduced cardiovascular mortality and HF
hospitalization [25]. The HEAAL study (n=3846) evaluated the effects of high-dose versus
low-dose losartan on clinical outcomes in patients with HF with ejection fraction (EF) ≤40%
[26]. High-dose ARB significantly reduced the rate of death or admission for HF, supporting
the value of dose up-titration to maximize benefit. Adverse events such as renal impairment,
hypotension and hyperkalemia occurred more commonly in the high-dose ARB arm, but did
not lead to excess treatment discontinuation. In head-to-head comparison of ACE-Is and
ARBs, ELITE II failed to demonstrate ARB superiority [27]. Similar to the data on ACE-Is,
two randomized trials investigating the use of ARBs in HFpEF were neutral with respect to
mortality [28,29].
For HF patients who remain symptomatic on an ACE-I, the addition of an ARB has the
potential to more completely inhibit RAAS. The Valsartan in Heart Failure Trial of >5000
HF patients showed that valsartan, when added to an ACE-I, had no effect on mortality but
reduced HF hospitalizations [30]. CHARM-Added supported this finding where dual RAAS
blockade with candesartan+ACE-I was associated with a reduction in cardiovascular death
or HF hospitalization [31]. However, these combinations have been associated with more
adverse events. Therefore, in clinical practice, dual blockade with an ACE-I and an ARB is
not commonly employed.
Despite treatment with ACE-Is/ARBs, patients with HF may demonstrate elevated
aldosterone levels [32]. The RALES trial in patients with systolic HF and severe symptoms
(NYHA classes III–IV) demonstrated a reduction in all-cause mortality with spironolactone
[3]. Spironolactone use was also associated with reduced HF hospitalization. The
EMPHASIS-HF trial supported the benefits of eplerenone in chronic systolic HF and mild
symptoms (NYHA class II), where there was a reduction in the primary endpoint of
cardiovascular death or HF hospitalization as well as a significant reduction in mortality and
hospitalizations [33]. Future studies will determine whether these benefits extend to HF
patients who are asymptomatic or have HFpEF [34].
The American College of Cardiology (ACC)/American Heart Association (AHA) as well as
European Society of Cardiology (ESC) guidelines recommend that ACE-Is (or an ARB, if
ACE-Is are not tolerated) should be started and continued indefinitely in HF patients with
LVSD unless contraindicated [35,36]. LVSD patients with symptomatic HF receiving an
ACE-I and a beta-blocker should also receive an MRA, except when moderate to severe
renal failure or hyperkalemia is present.
5. Myocardial infarction
Long-term trials of ACE-Is in high-risk patients with LVSD or HF after an MI demonstrated
a 20% risk reduction in mortality (~5–8% absolute risk reduction) as well as reduced stroke,
cardiovascular death, sudden cardiac death, recurrent MI, progression to severe HF and HF
hospitalization[37–39]. In acute MI complicated by LVSD, HF or both, the VALIANT trial
demonstrated similar benefits for captopril and valsartan on mortality and cardiovascular
events [40]. Combination therapy with an ACE-I+ARB increased the adverse event rate
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without improved survival. However, in the OPTIMAAL trial of captopril versus lostartan
in acute MI patients with HF, there was a non-significant difference in mortality in favor of
captopril [41]. In both trials, ACE-I and ARB use had similar effects on recurrent MI and re-
hospitalization [40,41]. ARBs were better tolerated with fewer patients discontinuing
therapy compared to ACE-Is in OPTIMAAL. In contrast, short-term post-MI trials of ACE-
Is (i.e. 6 weeks) that enrolled a broader population demonstrated a more modest mortality
reduction, with the greatest benefit seen in high-risk subgroups [42–44].
Supporting the role of MRAs post-MI, the EPHESUS trial in acute MI complicated by
LVSD and HF (or diabetes) found that eplerenone was associated with a reduction in
mortality, cardiovascular death/hospitalization and sudden death [45]. Two ongoing trials,
ALBATROSS [46] and REMINDER (Clinicaltrials.gov: NCT01176968), are investigating
whether early use of a MRA will improve outcomes in patients with an acute MI but without
HF.
The most recent ACC/AHA guidelines recommend that ACE-Is (or, if not tolerated, an
ARB) should be started and continued indefinitely in all ST-elevation MI (STEMI) patients
except those at lower risk (normal EF in whom cardiovascular risk factors are well
controlled and revascularization has been performed) and in those with non-STEMI with
clinical HF, LVSD, hypertension or diabetes, unless contraindicated [47,48]. The ESC
guidelines recommend ACE-I use in all post-STEMI patients (regardless of baseline risk) to
reduce the risk of recurrent MI (and other vascular events) [49]. MRAs have a class I
indication for STEMI and non-STEMI patients who are receiving therapeutic doses of ACE-
Is and beta-blockers, have an EF≤40%, and have either symptomatic HF or diabetes without
renal failure or hyperkalemia.
6. Hypertensive patients and others at increased cardiovascular risk
The benefits of blood pressure control on the risk of stroke, coronary heart disease and HF
have been established [50]. However, it has not been firmly established whether RAAS
inhibitors have a greater impact on events than alternative agents that produce similar
reductions in blood pressure.
6.1. Hypertension and stroke: ACE-Is and ARBs
The ALLHAT study showed no differences in coronary heart disease or mortality when
chlorthalidone, amlodipine, and lisinopril were compared [51]. However, the decrease in
blood pressure was not the same with the three agents, and many of the patients did not have
clinical disease. Similar findings were observed in the VALUE trial comparing valsartan and
amlodipine in 15,245 patients with hypertension [52]. In contrast, the ANBP-2 study found
that in older patients with hypertension, ACE-Is were superior to diuretics at reducing
cardiovascular events or deaths [53]. The SCOPE and PROGRESS trials in those with
hypertension and a history of stroke or transient ischemic attack, respectively, found that
ARB/ACE-I use was associated with a reduction in stroke compared to placebo [54,55]. The
LIFE study of losartan versus beta-blockers in hypertension patients found a risk reduction
in death, MI, or stroke in the losartan group [56]. The most recent recommendations from
the National Institute for Health and Clinical Excellence (NICE) indicate that for patients
Mentz et al. Page 5
Int J Cardiol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
<55 years, an ACE-inhibitor or a low cost ARB should be prescribed as first line based on
randomized controlled trial and cost-effectiveness evidence [57].
6.2. Arterial disease and others at increased cardiovascular risk: ACE-Is and ARBs
In the PEACE trial, there was no significant difference in the risk of cardiovascular death,
MI, or coronary revascularization among low-risk patients with stable CAD randomized to
ACE-Is [58]. In contrast, the HOPE study in a large population of patients with vascular
disease or diabetes in addition to 1 other cardiovascular risk factor found that ACE-I
treatment was associated with a reduction in cardiovascular death, nonfatal MI or stroke
[59]. Similar but smaller benefits were reported in the EUROPA study [60]. However, the
recently published TRANSCEND trial failed to show a benefit of telmisartan in patients
intolerant to ACE-Is who had similar entry criteria to the HOPE trial [61]. The interpretation
of this negative finding, inconsistent with those of previous RAAS trials in at risk patients, is
unclear. This negative trial should not divert from the robust evidence collected so far.
6.3. Diabetic nephropathy: ACE-Is and ARBs
In patients with diabetic nephropathy, data from randomized trials have demonstrated the
benefits of ACE-Is/ARBs on renal disease progression [62,63] and cardiovascular events
[64–66]. However, not all studies have supported this reduction in cardiovascular events
[66,67]. For instance, olmesartan use in the ROADMAP trial prevented new onset
microalbuminuria, but was associated with an unexpected higher cardiovascular mortality
compared to placebo [68]. However, ROADMAP was underpowered for a mortality
evaluation. These findings question the value of proteinuria as a surrogate for
nephroprotection and demonstrate the need for additional outcome trials. The ongoing VA
NEPHRON-D trial will help determine whether RAAS combinations may slow nephropathy
progression in advanced diabetic nephropathy [69].
6.4. Hypertension and renal disease: aldosterone antagonists
Aldosterone levels correlate with incident and resistant hypertension [70]. Several studies
have demonstrated the effectiveness of MRAs in lowering blood pressure as monotherapy as
well as add-on therapy [71–73]. In essential hypertension, eplerenone as monotherapy has
been shown to reduce blood pressure and left ventricular hypertrophy at least as well as an
ACE-I/ARB, with the combination superior to either agent alone [74–76]. Aldosterone has
also been implicated in the development and progression of renal disease in hypertensive
and diabetic patients [77,78]. MRAs have been shown to reduce albuminuria in these patient
populations [79,80]. The addition of spironolactone is an evidence-based strategy for the
management of resistant hypertension related to obesity, sleep apnea, and secondary
hyperaldosteronism [57,81]. However, randomized studies are needed to further investigate
MRAs in patients with hypertension and renal disease to establish whether these
medications impact outcomes and not just surrogate endpoints.
6.5. Hypertension and renal disease: direct renin inhibitors
Aliskiren has been shown to reduce BP and proteinuria in diabetics when added to losartan
[82–84]. Several clinical trials based on these pilot studies were designed to investigate the
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impact of aliskiren on cardiovascular outcomes. The ALTITUDE study (estimated n=8600)
investigating whether aliskiren added to an ACE-I/ARB reduces cardiovascular and renal
morbidity and mortality in high-risk diabetics [85] was stopped early by the Data
Monitoring Board given increased stroke, renal complications, hyperkalemia, and
hypotension with aliskiren. After the European Medicines Agency reviewed the data, they
recommended that in those with an indication for aliskiren (i.e. hypertension), it should not
be used in combination with an ARB or ACE-I if the patient also has diabetes or an
estimated glomerular filtration rate of <60 mL/min [86]. The Food and Drug Administration
indicated that aliskiren is contraindicated in combination with ACE-Is/ARBs for patients
with diabetes [88]. The APOLLO trial (estimated n=11,000) investigating the role of
aliskiren in preventing cardiovascular death, MI, stroke and HF in patients with
hypertension was also stopped early (ClinicalTrials.gov: NCT01259297).
7. Atrial fibrillation
There is evidence that RAAS inhibition may have an antiarrhythmic effect on AF. For
primary prevention of AF, post-hoc analyses of trials in patients with LVSD have shown an
association between ACE-I use and a reduced risk for incident AF [89,90]. Several small,
prospective studies of ACE-I/ARB use for secondary AF prevention demonstrated a
significant reduction in the risk of further AF and hospitalizations [91,92]. In 2005, a meta-
analysis of 11 randomized trials evaluating ACE-Is/ARBs for the prevention of AF (primary
and secondary) found that these agents reduced the risk of AF with greatest benefit in
patients with HF or left ventricular hypertrophy [93]. A more recent meta-analysis found
similar results [94]. While the mechanisms for such benefit are unclear, hypotheses include
an effect on atrial electrical remodeling [95]. However, the prospective GISSI-AF trial of
1442 patients in normal rhythm with a history of AF randomized to valsartan or placebo did
not demonstrate a reduction in AF recurrence with ARBs [96]. In terms of AF treatment, the
ACTIVE-I trial (n=9016) of irbesartan in patients with a history of AF was neutral with
respect to stroke/MI/death from vascular causes and this composite+HF hospitalization [97].
Regarding MRA use and AF, eplerenone was associated with a significant reduction in the
incidence of new onset AF in the EMPHASIS-HF trial [98]. Thus, these data support the
role for RAAS inhibition in primary prevention and potentially secondary prevention of AF,
but given continued controversy [99–101], widespread application will depend on definitive,
adequately powered randomized trials.
8. Adverse RAAS inhibitor effects
Dry cough, related to increased bradykinin levels, occurs in 5% to 15% of patients taking
ACE-Is, but not those taking ARBs [5]. Angioedema, a potentially life-threatening
complication occurs in a small percentage of patients receiving ACE-Is (estimated at 0.1%
to 0.5%). Given the potential for cross reactivity of angioedema with ARBs [102], patients
with history of ACE-I related angioedema should be prescribed ARBs only for clear
indications and under close monitoring [103].
Serious hyperkalemia, defined as a serum potassium ≥6.0 mmol/L, can occur with all RAAS
inhibitors especially in patients with renal insufficiency, diabetes or those taking potassium-
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sparing diuretics or potassium supplements. With patient education and close monitoring,
hyperkalemia from RAAS inhibitors can be predicted and averted in many cases [104].
Novel approaches such as the use of potassium binding resins are currently under
investigation. The PEARL-HF trial (n=105) evaluated the efficacy and safety of a potassium
binder (RLY 5016) in patients with chronic HF and prior hyperkalemia or chronic kidney
disease receiving spironolactone [105]. Potassium binder use was associated with
significantly lower potassium levels, a lower incidence of hyperkalemia and a higher
proportion of patients on higher spironolactone doses compared with placebo. The long term
efficacy and safety of this binder remains to be determined.
Progressive renal dysfunction can occur with ACE-Is/ARBs in the setting of hypovolemia or
renovascular hypertension. Although this complication is more common in HF patients, and
probably inherent to the pharmacological effect on renal hemodynamics, worsening renal
function is usually mild and reversible. It is unfortunately one of the main reasons for the
use of suboptimal doses. ACE-Is/ARBs and aliskiren are contraindicated during pregnancy.
Regarding spironolactone use, other adverse effects, particularly in men, include
gynecomastia and breast pain. Newer, more selective aldosterone receptor antagonists such
as eplerenone as well as others in development have improved sexual side effect profiles.
9. Monitoring and dose adjustment
In clinical practice, renal function and potassium levels should be monitored similar to the
manner used in clinical trials. In general, a metabolic panel should be obtained within 72 h
of initiation, after 4 weeks of therapy and every 3–4 months routinely. After dose
adjustments or pertinent changes in clinical status, laboratories should be obtained.
Medication doses should be decreased for a serum potassium >5.5 mmol/L and held for a
serum potassium >6.0 mmol/L. Since the initiation of ACE-inhibitors and ARBs can be
associated with an increase in serum creatinine, dose adjustment for renal function should be
individualized with intensification of monitoring in the setting of dynamic renal function
changes. Recommendations are to avoid aldosterone antagonists with a potassium ≥5.0
mEq/L or a creatinine >2.5 mg/dL in men or >2.0 mg/dL in women and to use them
cautiously in patients with more modest renal insufficiency [35,36].
10. Optimization of RAAS inhibition
RAAS inhibitors proven to improve outcomes are frequently underutilized or prescribed at
inadequate doses [106]. For example, in chronic HF, physicians are often reluctant to
aggressively titrate therapies in apparently stable patients. Data support that higher doses of
RAAS inhibition result in improved outcomes compared to lower doses [26,107]. Evidence-
based RAAS inhibitors should be titrated to doses attained in clinical trials or to the
maximally tolerated dose [35,36].
Those patients most likely to benefit from combined RAAS blockade, and specifically
which combination, are currently unknown. In trials of HF patients, an ARB+ACE-I did not
further reduce mortality, but combination therapy reduces HF hospitalizations and
composite endpoints including cardiovascular death [30,31,40]. However, the combination
is associated with more symptomatic hypotension and renal dysfunction [108]. Similarly, the
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combination of aliskiren with an ACE-I/ARB in high-risk patients increased adverse events
such that regulatory agencies have recommended against such combinations [86]. In the
EMPHASIS-HF trial of MRAs in patients with HF and LVSD, 94% of patients receiving
eplerenone were taking an ACE-I/ARB and there was a reduction in cardiovascular death or
HF hospitalization [45]. Similarly, in essential hypertension, combination therapy with an
MRA and an ACE-I/ARB appears superior to either agent alone [75]. Therefore, future
studies will need to explore the optimal balance of RAAS blockade in different patient
groups.
11. New RAAS inhibitors
While DRIs are not currently approved in HF, pilot studies have demonstrated the benefits
of aliskiren on surrogate endpoints (e.g. natriuretic peptides) [109] and trials with aliskiren
in both acute [110] and chronic [111] HF are ongoing. Despite concerns about aliskiren
therapy in combination with ACE-Is/ARBS, particularly in diabetics and those with renal
dysfunction, the importance of completion of these ongoing aliskiren trials in HF with
heightened safety monitoring has been reviewed [112]. The ASPIRE trial in 820 patients
with LVSD after MI found that a DRI added to standard therapy did not result in further
attenuation of LV end-systolic volume, and was associated with more adverse effects [113].
Novel ARBs such as azilsartan medoxomil have been compared with traditional ARBs and
appear to exhibit superior blood pressure reduction, yet data on cardiovascular morbidity or
mortality are lacking [114]. High-dose azilsartan was superior to high-dose valsartan or
olmesartan in lowering blood pressure in short-term studies [115–117]. Azilsartan reduces
blood pressure by 12–15 mm Hg/7–8 mm Hg, with additional reduction expected in
combination with a diuretic such as chlorthalidone [114].
Given the undesirable effects of spironolactone (e.g. gynecomastia, mastodynia, menstrual
disturbance) due to its poor selectivity for the mineralocorticoid receptor and the renal
tubular effects (i.e. hyperkalemia) with both spironolactone and eplerenone, third- and
fourth-generation MRAs are currently in development [118]. These non-steroidal agents will
aim for the potency of spironolactone and selectivity of eplerenone along with tubule-
sparing properties. The aims of the ongoing ARTS trial (ClinicalTrials.gov: NCT01345656)
are to evaluate a novel, non-steroidal, MRA with greater selectivity than spironolactone and
stronger mineralocorticoid receptor binding affinity than eplerenone in patients with HF.
Given eplerenone’s effect on lowering the burden of atherosclerosis [119], MRAs may also
have pleiotropic effects on cardiovascular and inflammatory diseases.
Another mechanism to antagonize aldosterone is to inhibit its formation by aldosterone
synthase. The novel aldosterone synthase inhibitor, LCI-699, was shown to suppress serum
aldosterone levels in a small proof-of-concept study in primary aldosteronism [120]. In a
randomized trial in primary hypertension, this agent was shown to significantly lower blood
pressure, but 20% of subjects developed blunted release of cortisol [121]. Therefore, the
development of LCI-699 was stopped in favor of developing more specific inhibitors.
In addition to ACE, there are other metallopeptidases such as neutral endopeptidase/
neprilysin (NEP) that convert vasoactive substances and could be a therapeutic target.
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Research on the dual NEP/ACE-I omapatrilat provides the basis for these novel agents.
Trials supported the benefits of omapatrilat in hypertension and HF [87,122]. However,
given that these peptidases are the major pathways responsible for bradykinin degradation,
dual blockade resulted in a higher incidence of angioedema. Therefore, substitution of an
ARB for the ACE-I in this combination, a so-called AT1R/NEP antagonist (ARNI) could
prove more favorable. The first in class ARNI, LCZ696, reduced blood pressure without an
increase in angioedema in one study of 1328 hypertensive patients [123]. Since ARNIs also
increase natriuretic peptide levels, these agents may prove beneficial in HF patients [124].
The PARAMOUNT phase 2 trial demonstrated that LCZ696 significantly reduced NT-
proBNP levels compared with valsartan at 12 weeks in HFpEF patients [125]. The
PARADIGM-HF trial is evaluating the efficacy and safety of LCZ696 on morbidity and
mortality in patients with HF and LVSD (ClinicalTrials.gov: NCT01035255).
Angiotensin-converting enzyme 2 is a recently recognized ACE homolog that appears
protective in HF [126]. Recent studies have shown that the increased levels of the soluble
form of the peptide-correlate with worsening HF symptoms, lower EF, higher natriuretic
peptide levels and adverse clinical events [127,128]. These results suggest that a
cardioprotective arm of the RAAS is active in HF and could be a target of future HF
therapies.
12. Developmental challenges and the approvability of new RAAS inhibitors
Multiple recent reviews have summarized issues related to the development and
approvability of novel RAAS inhibitors [124,129]. In brief, the key issues include the
complexities of trial design and background therapies, side effects and costs. The
investigation of novel agents in an existing field like RAAS inhibition means that drugs are
commonly evaluated as add-on therapy with current agents or as alternative therapy in those
intolerant to current therapies. Given that these compounds target the same axis, there are
questions about the magnitude of blood pressure or HF efficacy that remains for new agents.
Logistically, it is important that the background therapies in these trials occur at the
maximum tolerated doses or defined optimal doses. These considerations are particularly
relevant since even in the setting of controlled trials, dosing is frequently not optimized due
to clinical inertia and intolerance (real or perceived). Furthermore, as has been seen in
multiple trials of add-on RAAS therapy, the side effect profile may become less favorable
with the combination of multiple agents [108]. The potential side effects of these agents are
also ill-defined. How is hypotension defined and does it need to be symptomatic? What is
the clinical relevance of a small decrease in estimated glomerular filtration rate with
combination RAAS inhibition? As the therapeutic window narrows with combination RAAS
inhibition, it will likely become increasingly difficult to demonstrate efficacy in a broad
population. Trials may need to increasingly focus on patient subgroups with specific
cardiovascular phenotypes most likely to benefit from novel therapies without adverse
events.
Mentz et al. Page 10
Int J Cardiol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
13. Conclusions
The RAAS is central to the pathogenesis of cardiovascular disease. Contemporary RAAS
inhibition includes monotherapy and various combination regimens with ACE-Is, ARBs and
MRAs. We highlighted key trials of RAAS inhibition in various at-risk populations
including those with HF, MI and hypertension. Optimization of RAAS inhibition can be
obtained through medication uptitration and combination with close monitoring for side
effects. Pilot studies of novel RAAS inhibitors as well as ongoing morbidity and mortality
trials with DRIs, novel MRAs and ARBs, aldosterone synthase inhibitors and ARNIs
demonstrate the ever-changing landscape of this field. The development of these agents is
challenged by complex trial designs and background therapies, side effect profiles and high
costs. The history of RAAS inhibition demonstrates how the field has evolved from the early
days where ACE-Is resulted in striking mortality benefits to one where complex
polypharmacy and individualized regimens are increasingly the norm.
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Fig. 1.
Biochemical mechanisms for the production of angiotensin peptides. Illustrated are the
recognized enzymatic pathways leading to the formation and metabolism of products
derived from angiotensinogen. ACE cleaves angiotensin I to generate angiotensin II
(angiotensin-[1–8]), while neutral endopeptidases (NEP) cleave angiotensin I to produce
angiotensin-(1–7). ACE hydrolyzes the heptapeptide into biologically inactive angiotensin-
(1–5). ACE-2 catalyzes the conversion of angiotensin I to angiotensin-(1–9) and converts
angiotensin II into angiotensin-(1–7). The proinflammatory actions of angiotensin II are
mediated primarily through the AT1 receptor, whereas the anti-inflammatory actions of
angiotensin-(1–7) are exerted through receptors that include a mas oncogene-encoded G
protein-coupled receptor. AT-R = angiotensin type receptor and mas-R = mas receptor.
Reprinted from Am J Cardiol, Vol 98, Ferrario CM et al., Role of the renin–angiotensin–
aldosterone system and proinflammatory mediators in cardiovascular disease, pages 121-8,
Copyright (2006) [1] with permission from Elsevier.
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Fig. 2.
Pharmacological agents (open boxes) used to manipulate the RAAS (shaded boxes). Dashed
lines signify inhibitory pathways. EDHF indicates endothelium-derived hyper-polarizing
factor and SNS, sympathetic nervous system.
Reproduced with permission from Givertz, Circulation 2001 [5].
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Table 1
Pivotal trials of renin angiotensin aldosterone inhibitors.
Trial name Drug studied Patient population Primary conclusion(s)
Heart failure trials
CONSENSUS [2] Enalapril (2.5–40 mg daily;
mean
18.4 mg daily) vs. placebo.
N=253. Severe congestive heart
failure (NYHA IV).
Mean follow-up 188 days.
The primary endpoint of mortality at 6
months occurred
in 26% of the patients receiving enalapril vs.
44% of the
placebo group (RRR=40%; P=0.002).
The RRR over the entire duration of follow-
up was 27%
with an ARR of 15%.
SOLVD [22] Enalapril (2.5–20 mg daily;
mean
11.2 mg daily) vs. placebo.
N=2569. Chronic HF and
EF≤35%. Mean follow-up
41.4 months.
4.5% ARR in mortality with enalapril (35.2%
vs. 39.7%
mortality; RRR=16%; P<0.0036).
PEP-CHF [24] Perindopril (4 mg daily) vs.
placebo.
At 1 year, almost 90% of
patients
were treated with perindopril
4 mg.
N=850. Patients ≥70 years with a
diagnosis of HF with
diastolic dysfunction. Median
follow-up 2.1 years.
For the entire duration of follow-up, 25.1%
patients
assigned to placebo and 23.6% to perindopril
experienced
the composite of all-cause mortality or
unplanned HF-related hospitalization (HR
0.92; 95% CI,
0.70–1.21; P=0.545).
Val-HeFT [30] Valsartan 160 mg BID vs.
placebo.
Target valsartan dose was
achieved
in 84% of patients.
N=5010. HF patients with
NYHA class II–IV symptoms
and LVEF<40%. Patients had to
have been receiving a
fixed-dose drug regimen that
could include ACE inhibitors,
diuretics, digoxin, and beta-
blockers for at least
two weeks. Mean follow-up 23
months.
19.7% of patients assigned to valsartan and
19.4% of
patients assigned to placebo died (RR 1.02;
98% CI,
0.88–1.18; P=0.80).
For a combined endpoint of mortality and
morbidity,
28.8% of patients assigned to valsartan and
32.1% of
patients assigned to placebo experienced the
composite
(ARR=3.3%; RR 0.87; 97.5% CI, 0.77–0.97,
P=
0.009).
HEAAL [26] Losartan 150 mg vs. 50 mg
daily
(target doses). The mean doses
in
these two groups were 129 mg
and
46 mg, respectively.
N=3846. HF patients with
NYHA classes II–IV symptoms,
EF≤40%, and intolerance to
ACE-inhibitors. Median
follow-up 4.7 years.
For the primary endpoint, 43% patients in the
150 mg
group vs. 46% in the 50 mg group died or
were admitted
for heart failure (ARR=3%; HR 0.90, 95% CI
0.82–0.99;
P=0.027).
ELITE II [27] Losartan 50 mg daily vs.
captopril
50 mg TID.
N=3152. HF patients aged ≥60
years with NYHA classes
II–IV symptoms, and EF≤40%.
Median follow-up
555 days.
For the primary endpoint of all-cause
mortality, 17.1% of
losartan and 15.9% of captopril patients
experienced the
endpoint (HR 1.13; 95% CI, 0.95–1.35;
P=0.16).
CHARM-Alternative
[25]
Candesartan 32 mg daily vs.
placebo.
At 6 months, the mean
candesartan
daily dose was 23 mg.
N=2028. Symptomatic HF
patients with EF≤40% who
were not receiving ACE-
inhibitors because of previous
intolerance. Median follow-up
33.7 months
For the primary composite endpoint of CV
death or
hospital admission for HF, 33.0% of
candesartan patients
and 40.0% of placebo patients experienced
the composite
(ARR=7%; unadjusted HR 0.77; 95% CI,
0.67–0.89;
P=0.0004).
CHARM-Added [31] Candesartan 32 mg daily vs.
placebo.
At 6 months, the mean
candesartan
daily dose was 24 mg.
N=2548. HF patients with
NYHA classes II–IV symptoms,
EF≤40%, and who were being
treated with
ACE-inhibitors. Median follow-
up 41 months.
For the primary composite endpoint of CV
death or
hospital admission for HF, 37.9% of
candesartan
patients and 42.3% of placebo patients
experienced the
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Trial name Drug studied Patient population Primary conclusion(s)
composite (ARR=4.4%; unadjusted HR 0.85;
95% CI,
0.75–0.96; P=0.011).
CHARM-Preserved
[28]
Candesartan 32 mg daily vs.
placebo.
At 6 months, the mean
candesartan
daily dose was 25 mg.
N=3023. HF patients with
NYHA classes II–IV symptoms,
and EF>40%. Median follow-up
36.6 months.
For the primary composite endpoint of CV
death or
hospital admission for HF, 22.0% of
candesartan patients
and 24.3% of placebo patients experienced
the
composite (unadjusted HR 0.89; 95% CI,
0.77–1.03;
P=0.118).
I-PRESERVE [29] Irbesartan 300 mg daily vs.
placebo.
N=4128. HF patients ≥60 years,
NYHA classes II–IV
symptoms, and EF≥45%. Mean
follow-up 49.5 months.
For the primary composite outcome of death
from any
cause or hospitalization for a CV cause
occurred in 36%
of the irbesartan patients and 37% of the
placebo
patients (HR 0.95; 95% CI, 0.86–1.05;
P=0.35).
RALES [3] Spironolactone 25–50 mg daily
(mean dose 26 mg) vs. placebo.
N=1663. Severe HF patients
(NYHA classes III–IV) with
EF≤35% who were being treated
with an ACE-inhibitor.
Trial was discontinued early,
after a mean follow-up
period of 24 months.
The primary end point of death from all
causes occurred
in 35% of the spironolactone group and 46%
of the
placebo group (ARR=11%; RR 0.70; 95% CI,
0.60–0.82;
P<0.001).
EMPHASIS [33] Eplerenone (up to 50 mg daily)
vs. placebo.
N=2737. HF patients with
NYHA class II symptoms and
EF≤35%. Trial was discontinued
early, after a median
follow-up period of 21 months.
The primary composite outcome of death
from CV
causes or hospitalization for HF occurred in
18.3%
of patients in the eplerenone group and 25.9%
in
the placebo group (ARR=7.6%; HR 0.63;
95% CI,
0.54–0.74; P<0.001).
Myocardial infarction
SAVE [37] Captopril vs. placebo. Target
dose of
captopril 150 mg daily reached
in
79% of patients.
N=2231. Patients with EF≤40%
within 3 to 16 days
after MI, but without overt HF or
symptoms of myocardial
ischemia. Average follow-up 42
months.
5% ARR in mortality with captopril (20% vs.
25%
mortality; risk reduction=19%; P=0.019).
AIRE [38] Ramipril vs. placebo. Initial
dose
of 2.5 mg BID up to 5 mg BID.
N=2006. Patients within 3–10
days of an acute MI with
clinical evidence of HF. Average
follow-up 15 months.
6% ARR in mortality with ramipril (17% vs.
23%
mortality; risk reduction=27%; P=0.002).
TRACE [39] Trandolapril vs. placebo. Initial
dose
of trandolapril 1 mg daily up to
4 mg daily.
N=1749. Patients with acute MI
and EF≤35% randomized
on days 3–7 after MI. The
duration of
follow-up was 24 to 50 months.
7.6% ARR in mortality with trandolapril
(34.7% vs. 42.3%
mortality; RR 0.78; 95% CI, 0.67–0.91;
P=0.001).
VALIANT [40] Valsartan vs. valsartan plus
captopril
vs. captopril.
3-month target doses of
valsartan
160 mg BID, valsartan 80 mg
BID
and captopril 50 mg TID, or
captopril
50 mg TID.
N=14,703. Patients with MI
complicated by LVSD, HF,
or both randomized at 0.5 to 10
days after acute MI.
Median follow-up 24.7 months.
For the primary end point of death from any
cause, the
mortality rates in the valsartan, captopril, and
combination therapy groups were 19.9%,
19.5% and
19.3%, respectively.
HR for valsartan group vs. captopril group,
1.00; 97.5%
CI, 0.90–1.11; P=0.98; HR for combination
group vs.
captopril group, 0.98; 97.5% CI, 0.89–1.09;
P=0.73.
OPTIMAAL [41] Losartan (target 50 mg daily) vs.
captopril (target 50 mg TID).
N=5477. Patients ≥50 years with
acute MI and HF.
For the primary end point of death from any
cause, the
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Mean follow-up 2.7 years. mortality rate was 18% in the losartan group
and 16% in
the captopril group (RR 1.13; 95% CI, 0.99–
1.28; P=0.07).
EPHESUS [45] Eplerenone (25 mg daily,
titrated
to 50 mg daily). vs. placebo
N=6632. Patients with acute MI
complicated by LVSD
and HF. Mean follow-up 16
months.
The primary end points of death from any
cause and
death from CV causes or hospitalization for
CV causes
occurred in 14.4% of the eplerenone group vs.
16.7% of
the placebo group (ARR=2.3%; RR 0.85;
95% CI,
0.75–0.96; P=0.008) and 26.7% of the
eplerenone
group vs. 30.0% of the placebo group
(ARR=3.3%;
RR 0.87; 95% CI, 0.79–0.95; P=0.002),
respectively.
Hypertension and stroke
ALLHAT [51] Chlorthalidone (12.5–25 mg
daily)
vs. amlodipine (2.5–10 mg
daily)
vs. lisinopril (10–40 mg daily).
N=33,357. Patients ≥55 years
with hypertension and
at least 1 other coronary heart
disease risk
factor. Mean follow-up 4.9 years.
There was no difference in the primary
outcome of fatal
coronary heart disease or nonfatal MI
between treatments.
Compared with chlorthalidone (6-year rate,
11.5%), the RR
was 0.99; 95% CI, 0.91–1.08 for lisinopril.
VALUE [52] Valsartan vs. amlodipine. N=15,245. Patients ≥50 years
with hypertension and a
high risk of cardiac events. Mean
follow-up 4.2 years
The primary composite endpoint of cardiac
mortality
and morbidity occurred in 10.6% of the
valsartan group
and 10.4% of the amlodipine group (HR 1.04;
95% CI,
0.94–1.15; P=0.49).
ANBP-2 [53] ACE-inhibitor vs. diuretic.
Enalapril
and hydrochlorothiazide were
recommended as initial therapy.
N=6083. Patients with
hypertension who were 65 to
84 years of age. Median follow-
up 4.1 years.
The primary end point of all CV events or
death from
any cause occurred in 56.1 per 1000 patient-
years in the
ACE-inhibitor group and 59.8 per 1000
patient-years in
the diuretic group (HR 0.89; 95% CI, 0.79–
1.00; P=
0.05).
SCOPE [54] Candesartan (8–16 mg daily)
vs. placebo.
N=4964. Patients aged 70–89
years, with systolic
blood pressure 160–179 mm Hg,
and/or diastolic blood
pressure 90–99 mm Hg, and a
Mini Mental State
Examination test score ≥24.
Mean follow-up 3.7 years.
The primary outcome of CV death, non-fatal
stroke and
non-fatal MI occurred at a rate of 26.7 events
per 1000
patient-years in the candesartan group and
30.0 events
per 1000 patient-years in the placebo group.
Risk reduction=
10.9%; 95% CI, −6.0 to 25.1, P=0.19.
PROGRESS [55] Perindopril (4 mg daily), +/−
indapamide vs. placebo.
N=6105. Hypertensive and non-
hypertensive patients
with a history of stroke or
transient ischemic attack.
Mean follow-up 3.9 years
The primary outcome of stroke (fatal or non-
fatal) occurred
in 10% of the treatment group and 14% of the
placebo group
(ARR=4%; RRR=28%; 95% CI, 17–38;
P<0.0001).
LIFE [56] Losartan-based (50 mg daily)
vs. atenolol-based (50 mg daily)
antihypertensive treatment.
N=9193. Patients aged 55–80
years with essential
hypertension and left ventricular
hypertrophy on
electrocardiography. Mean
follow-up 4.8 years.
The primary outcome of CV event (death,
myocardial
infarction, or stroke) occurred in 11% of the
losartan
group and 13% of the atenolol group
(ARR=2%;
unadjusted RR 0.87; 95% CI, 0.77–0.98;
P=0.021).
Arterial disease and others at increased cardiovascular risk
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PEACE [58] Trandolapril (4 mg daily) vs.
placebo.
N=8290. Patients ≥50 years with
stable coronary
artery disease and EF>40%.
Median follow-up 4.8 years.
The primary end point of death from CV
causes, MI,
or coronary revascularization occurred in
21.9% of the
trandolapril group and 22.5% of the placebo
group (HR
0.96; 95% CI, 0.88–1.06; P=0.43).
HOPE [59] Ramipril (10 mg daily) vs.
placebo.
The percentage of patients who
were receiving 10 mg of
ramipril
per day
was 82.9% at one year.
N=9297. Patients ≥55 years who
had evidence of
vascular disease or diabetes plus
one other CV risk factor
and who were not known to have
a low ejection
fraction (EF>40%) or HF.
Follow-up period 5 years.
The primary outcome of MI, stroke, or death
from CV
causes occurred in 14.0% of those in the
ramipril group
and 17.8% in the placebo group (ARR=3.8%;
RR 0.78;
95% CI, 0.70–0.86; P<0.001).
EUROPA [60] Perindopril (8 mg daily) vs.
placebo.
N=12,218. Patients with stable
coronary artery disease,
but no clinical HF. Mean follow-
up 4.2 years.
The primary endpoint of CV death, MI, or
cardiac
arrest occurred in 8% of the perindopril group
and 10%
of the placebo group (ARR=2%; RRR=20%;
95% CI, 9–
29; P=0.0003).
TRANSCEND [61] Telmisartan (80 mg daily) vs.
placebo.
N=5926. High-risk patients with
cardiovascular disease
or diabetes with end-organ
damage and intolerance to
ACE-inhibitors. Median follow-
up 56 months.
The primary outcome of the composite of CV
death, MI,
stroke, or hospitalization for HF occurred in
15.7% in the
telmisartan groups and 17.0% in the placebo
group (HR
0.92; 95% CI, 0.81–1.05; P=0.216).
Diabetic nephropathy
RENAAL [62] Losartan (50–100 mg daily) vs.
placebo.
N=1513. Patients with type 2
diabetes and
nephropathy. Mean follow-up 3.4
years.
The primary outcome of the composite of a
doubling of the
base-line serum creatinine concentration, end-
stage renal
disease, or death occurred in 43.5% of the
losartan group
and 47.1% of the placebo group (ARR=3.6%;
risk reduction
16%; 95% CI 2–28; P=0.02).
Irbesartan Diabetic
 Nephropathy Trial
[63]
Irbesartan (300 mg daily) vs.
amlodipine (10 mg daily) vs.
placebo.
N=1715. Hypertensive patients
with nephropathy
due to type 2 diabetes. Mean
follow-up 2.6 years.
The primary composite end point of a
doubling of
the base-line serum creatinine concentration,
the
development of end-stage renal disease, or
death
from any cause occurred in 32.6% of the
irbesartan group,
41.1% of the amlodipine group, and 39.0% of
the placebo group. The irbesartan group had
an ARR
of 6.4% and a RR of 0.80; 95% CI, 0.66–
0.97; P=0.02 vs.
placebo and an ARR of 8.5% with a RR 0.77;
95% CI, 0.63–
0.93; P=0.006 vs. amlodipine.
ABCD Substudy [64] Nisoldipine vs. enalapril. N=470. Patients with non-
insulin-dependent
diabetes and hypertension. Five
year follow-up.
The endpoint of this analysis was fatal or
non-fatal MI, a
secondary endpoint of the ABCD trial. 10.6%
of
patients in the nisoldipine group (25 events)
experienced the outcome compared with
2.1%
in the enalapril group (5 events). ARR=8.5%
with unadjusted risk ratio of 5.5; 95% CI,
2.1–14.6.
FACET [65] Fosinopril (20 mg daily)
vs. amlodipine (10 mg daily).
N=380. Patients with
hypertension and
The secondary endpoint of CV events (acute
MI, stroke,
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non-insulin-dependent diabetes
followed for
up to 3.5 years.
or hospitalized angina) occurred in 7.4% of
the fosinopril
group and 14.1% of the amlodipine group
(HR 0.49; 95%
CI, 0.26–0.95).
UKPDS 39 [67] Atenolol vs. captopril. N=1148. Hypertensive patients
with type 2
diabetes.
One of the primary outcomes was all-cause
mortality
which occurred in 18.8% of the captopril
group and
16.5% of the atenolol group (RR for captopril
1.14, 95% CI
0.81–1.61; P=0.44).
ROADMAP [68] Olmesartan (40 mg daily)
vs. placebo.
N=4447. Patients with type 2
diabetes and
normoalbuminuria. Median
follow-up 3.2 years
The primary outcome was the time to the first
onset of
microalbuminuria. Microalbuminuria
developed in 8.2%
of the olmesartan group and 9.8% of the
placebo group
(HR for onset of microalbuminuria, 0.77;
95% CI, 0.63–
0.94; P=0.01). The secondary composite
endpoint of death from CV causes occurred in
0.7% of
the olmesartan group (15 events) and 0.1% of
the placebo
group (3 events). HR 4.94; 95% CI, 1.43–
17.06; P=
0.01.
Atrial fibrillation
GISSI-AF [96] Valsartan (target 320 mg daily)
vs. placebo.
N=1442. Patients who were in
sinus rhythm but had
had either ≥2 documented
episodes of AF in the
previous 6 months or successful
cardioversion for AF in
the previous 2 weeks. Patients
also had to have underlying
CV disease, diabetes, or left
atrial enlargement.
One year follow-up.
The co-primary endpoint of AF recurrence
occurred in
51.4% of the valsartan group and 52.1% of
the placebo
group (HR 0.98; 96% CI, 0.85–1.14; P=0.83).
ACTIVE-I [97] Irbesartan (target dose 300 mg
daily) vs. placebo.
N=9016. Patients with a history
of risk factors for
stroke and a systolic blood
pressure of at least
110 mm Hg. Mean follow-up 4.1
years.
The coprimary outcome of stroke, myocardial
infarction,
or death from vascular causes occurred at a
rate of 5.4%
per 100 person-years in both groups (RR with
irbesartan,
0.99; 95% CI, 0.91–1.08; P=0.85).
Abbreviations: NYHA = New York Heart Association, HF = heart failure, EF = ejection fraction, HR = hazard ratio, ARR = absolute risk
reduction, RR = relative risk, CI = confidence interval, CV = cardiovascular, MI = myocardial infarction, AF = atrial fibrillation, LVSD = left
ventricular systolic dysfunction, BID = twice daily, and TID = three times daily.
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